Alzheimer disease: Lessons from immunotherapy for Alzheimer disease

Nature Reviews Neurology

Volumn 10, Issue 4, 2014, Pages 188-189

  Wang, Yan Jiang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BAPINEUZUMAB; MEMBRANE METALLOENDOPEPTIDASE; SOLANEZUMAB;

ALZHEIMER DISEASE; AMYLOID PLAQUE; BRAIN EDEMA; COGNITION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EFFUSION; HUMAN; MILD COGNITIVE IMPAIRMENT; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SHORT SURVEY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; IMMUNOTHERAPY; TREATMENT FAILURE;

EID: 84898003901     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2014.44     Document Type: Short Survey

References (10)

1. Salloway, S. et al. Two phase 3 trials of bapineuzumab in mild to moderate Alzheimer's disease. N. Engl. J. Med. 370, 322-333 (2014
2. Doody, R. S. et al. Phase 3 trials of solanezumab for mild to moderate Alzheimer's disease. N. Engl. J. Med. 370, 311-321 (2014
3. Demattos, R. B. et al. A plaque-specific antibody clears existing β-Amyloid plaques in Alzheimer's disease mice. Neuron 76, 908-920 (2012
4. Yamada, K. et al. Aβ immunotherapy: Intracerebral sequestration of Aβ by an anti-Aβ monoclonal antibody 266 with high affinity to soluble Aβ. J. Neurosci. 29, 11393-11398 (2009
5. Gardberg, A. S. et al. Molecular basis for passive immunotherapy of Alzheimer's disease. Proc. Natl Acad. Sci. USA 104, 15659-15664 (2007
6. Zago, W. et al. Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities. Alzheimers Dement. 9, S105-S115 (2013
7. Liu, Y. H., Giunta, B., Zhou, H. D., Tan, J. & Wang, Y. J. Immunotherapy for Alzheimer disease: The challenge of adverse effects. Nat. Rev. Neurol. 8, 465-469 (2012
8. Sehgal, N. et al. Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc. Natl Acad. Sci. USA 109, 3510-3515 (2012
9. Henderson, S. J. et al. Sustained peripheral depletion of amyloid-β with a novel form of neprilysin Does not affect central levels of amyloid-β. Brain 137, 553-564 (2013
10. Krstic, D. & Knuesel, I. Deciphering the mechanism underlying late-onset Alzheimer disease. Nat. Rev. Neurol. 9, 25-34 (2012.